News

CLINUVEL
Posted by CLINUVEL
August 29, 2018

Appendix 4E and Preliminary Financial Report

29 August 2018 The Directors of the Board present their report on...

Read More
CLINUVEL
Posted by CLINUVEL
August 21, 2018

CLINUVEL Investor Summary

21 August 2018 Increasing interest has been seen in the interaction between...

Read More
CLINUVEL
Posted by CLINUVEL
July 30, 2018

Appendix 4C

30 July 2018 CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL...

Read More
CLINUVEL
Posted by CLINUVEL
July 27, 2018

CLINUVEL Newsletter - July 2018

27 July 2018 On 25 June 2018 CLINUVEL announced its New Drug...

Read More
CLINUVEL
Posted by CLINUVEL
July 17, 2018

Change in substantial holding

17 July 2018 Enclosed is a notice of a change of interest...

Read More
CLINUVEL
Posted by CLINUVEL
July 6, 2018

Change in Director's Interest Notice

6 July 2018 Enclosed is a change in director’s interest notice.  Download...

Read More
CLINUVEL
Posted by CLINUVEL
July 4, 2018

Change in substantial holding

04 July 2018 Enclosed is a notice of a change in substantial...

Read More
CLINUVEL
Posted by CLINUVEL
June 25, 2018

CLINUVEL COMPLETES SCENESSE® FDA FILING

25 June 2018 EXECUTIVE SUMMARY First NDA for SCENESSE® (afamelanotide 16mg) in...

Read More
CLINUVEL
Posted by CLINUVEL
June 22, 2018

Trading Halt

22 June 2018 Pursuant to Listing Rule 17.1, Clinuvel Pharmaceuticals Ltd (CUV)...

Read More
CLINUVEL
Posted by CLINUVEL
June 1, 2018

Appendix 3B

01 June 2018 Enclosed is a new issue announcement regarding an application...

Read More